
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
EVOGLIPTIN TARTRATE A NEW DRUG OF DPP-4 INHIBITOR: AN OVERVIEW
Kinjal Thakkar*, Khushbu Patel, U. B. Patel and Dr. C. N. Patel
Abstract DPP4 inhibitors (DPP4i) are a modern class of diabetes medications that retain incretin hormones while increasing postprandial insulin secretion. Gliptins also known as DPP-IV inhibitors is a class of antidiabetic drug. DPP-IV inhibitor like Evogliptin tartrate chemically known as (3R)-4-[(3R)-3-amino- 4-(2,4,5-trifluorophenyl) butanoyl]-3- [(2-methylpropan-2-yl) oxymethyl] piperazin-2-one;(2R,3R)-2,3- dihydroxybutanedioic acid is used as a monotherapy. This article explains about chemistry, pharmacology, safety information and drugdrug interaction of Evogliptin tartrate. Keywords: Type 2 diabetes, DPP-4 inhibitors, Classification of antidiabetics, Drug interaction. [Full Text Article] [Download Certificate] |
